Sexual dysfunction worsen both the general and specific quality of life of women with irritable bowel syndrome. A cross-sectional study-Reference-Cited by-同舟云学术

Sexual dysfunction worsen both the general and specific quality of life of women with irritable bowel syndrome. A cross-sectional study

Published:2022-09-23 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Camacho Santiago¹,Díaz Andrea²,Pérez Paulina²,Batalla Héctor³,Flores Yoshua⁴,Altamirano Evelyn⁵,Tijera María de Fátima Higuera-de la¹,Murguía Daniel¹,Gómez-Laguna Laura¹

Affiliation:

1. Hospital General de México

2. Ibero American University

3. National Autonomous University of Mexico

4. Instituto Politécnico Nacional

5. Mexican Social Security Institute

Abstract

Abstract Background: Irritable bowel syndrome (IBS) and sexual dysfunction (SxD) lowers quality of life (QOL) separately, but the effect of their overlap in unselected populations has not been studied. Objective: To evaluate the QOL of IBS women with and without SxD and compare it with controls. Methods: In this cross-sectional assessment, we studied 51 IBS women (Rome IV criteria) and 54 controls. SxD was determined using the female sexual function index questionnaire. QOL was evaluated by the Short Form 36 (SF-36) and IBS-QOL questionnaires. Results: SxD prevalence was similar between IBS women (39.22%) and controls (38.89%). Compared with other groups, IBS patients with SxD showed lower scores in all domains as well as in the physical, mental summaries of the SF-36 and almost all domains (except for body image, food avoidance, and social reaction compared with IBS patients without SxD) and the total score of IBS-QOL. Conclusions: These findings show that SxD worsens both general and specific QOL of women with IBS. The consideration of SxD in patients with IBS will allow us to make a more effective diagnostic and therapeutic approach. Clinical trial registry in Mexico City General Hospital: DI/19/107/03/080. Clinical trials registration: NCT04716738.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Global burden of irritable bowel syndrome: trends, predictions and risk factors;Black CJ;Nat Rev Gastroenterol Hepatol. Nature Research,2020

2. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. 5: Lancet Gastroenterol Hepatol. Elsevier Ltd;; 2020. pp. 908–17.

3. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J,. Gastroenterology. et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. 160: W.B. Saunders; 2021. 99–114.e3.

4. Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome;Shin A;Clin Gastroenterol Hepatol,2020

5. Defrees DN, Bailey J. Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Primary Care - Clinics in Office Practice. Elsevier; 2017. pp. 655–71.